#JITC Research: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment https://t.co/5Mc0RCfJQy https://t.co/FJ1OtzqRfD
RT @jitcancer: New #JITC Research: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and n…
RT @jitcancer: New #JITC Research: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and n…
Immunopeptidomic analysis of patient-derived colorectal #cancer organoids reveals a sparse HLA class I #neoantigen landscape and no increase in neoantigen load after interferon or MEK-inhibitor treatment: https://t.co/qkNnDrAT7V @jitcancer @ICR_London #OA
RT @jitcancer: New #JITC Research: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and n…
RT @jitcancer: New #JITC Research: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and n…
New #JITC Research: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment https://t.co/5Mc0RCfJQy @MarcoGerlinger https://t.co/2X6nB3v6XX
RT @MarcoGerlinger: Great pancancer analysis from @JimmyVdE No evidence for selection against neoantigen encoding mutations. Computational…
Very good argument for not trusting computational neoantigen calling....
RT @MarcoGerlinger: Great pancancer analysis from @JimmyVdE No evidence for selection against neoantigen encoding mutations. Computational…
Great pancancer analysis from @JimmyVdE No evidence for selection against neoantigen encoding mutations. Computational neoantigen overcalling which we found by mass spec https://t.co/NOW5rHkvwa likely contributes to this
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
New in @jitcancer from Dr. @MarcoGerlinger's lab! Immunopeptidomics of colorectal cancer #organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. https://t.co/igGEWM4l2t https:
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @ICR_London: @MarcoGerlinger @royalmarsdenNHS The research was published, #OpenAccess, in the @BioMedCentral Journal for ImmunoTherapy o…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @iskander: The numbers make sense if you think about how many other peptides are competing for presentation, most "neoepitopes" are wish…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @iskander: The numbers make sense if you think about how many other peptides are competing for presentation, most "neoepitopes" are wish…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @McclellandLab: “MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @generoom: Another nail in the coffin of TMB testing...#cancer #diagnostics https://t.co/wkjnUe7RQw
Another nail in the coffin of TMB testing...#cancer #diagnostics
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @iskander: The numbers make sense if you think about how many other peptides are competing for presentation, most "neoepitopes" are wish…
The numbers make sense if you think about how many other peptides are competing for presentation, most "neoepitopes" are wishful thinking.
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
“MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than computational prediction. May explain poor responses of MSS CRC to IO.” Great work from Gerlinger lab.
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
RT @MarcoGerlinger: MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than comput…
MHC ligandome mass spec in CRC organoids: Only 3/612 mutations encode for detectable neoantigens. 64x lower than computational prediction. May explain poor responses of MSS CRC to IO. Our and @michal_bassani 's new paper in @jitcancer. https://t.co/qcehZD0
RT @ICR_London: @MarcoGerlinger @royalmarsdenNHS The research was published, #OpenAccess, in the @BioMedCentral Journal for ImmunoTherapy o…
RT @ICR_London: @MarcoGerlinger @royalmarsdenNHS The research was published, #OpenAccess, in the @BioMedCentral Journal for ImmunoTherapy o…
@MarcoGerlinger @royalmarsdenNHS The research was published, #OpenAccess, in the @BioMedCentral Journal for ImmunoTherapy of Cancer: 'Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape…' https://t.co/x69a1t
Great new work by @michal_bassani and her group in search of mutated neoantigens in patient-derived CRC organoids: They could validate only 3/614 non-silent mutations by MS (lower bound of ~0.5%). Novel food for thought. https://t.co/yxW0OKVSAR